Applied Molecular Transport Inc.

Thomas Carl Hunter

Randall J Mrsny

Weijun Feng

Tahir Mahmood

Sally Rhiannon Postlethwaite

Charles Olson

Keyi Liu

Julia Dawn Mackay

Alistair Taverner

The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.

Cholix-derived carriers for oral delivery of heterologous payload

The present disclosure relates to isolated non-naturally occurring delivery constructs comprising a bacterial toxin-derived delivery construct coupled to a biologically active therapeutic cargo; wherein the delivery construct is capable of delivering the biologically active cargo via transcytosis transport across an epithelial cell; and wherein the delivery construct does not comprise a bacterial toxin-derived translocation domain or a bacterial toxin-derived catalytic (cytotoxic) domain.

Toxin-derived delivery constructs for pulmonary delivery

Growing community of inventors

Mountain View, CA, United States of America

Thomas Carl Hunter